Overview

Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
Phase:
Phase 1
Details
Lead Sponsor:
Tracon Pharmaceuticals Inc.
Treatments:
Pemetrexed